https://www.aigom.it/wp-content/uploads/2025/02/Screenshot-2025-02-27-094112.png680749Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-02-27 09:07:102025-03-04 09:27:03SCUOLA DI METODOLOGIA DELLA RICERCA CLINICA 2025-11° EDIZIONE VENERDI 14-SABATO 15 FEBBRAIO 2025
https://www.aigom.it/wp-content/uploads/2025/02/25.02.png1353960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-02-25 08:25:392025-02-25 08:25:39BREAST CANCER BRAIN METASTASIS: A COMPREHENSIVE REVIEW.
https://www.aigom.it/wp-content/uploads/2025/02/ART18.2.png1201960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-02-18 08:50:152025-02-18 08:50:15SURVIVAL WITH CEMIPLIMAB IN RECURRENT CERVICAL CANCER.
https://www.aigom.it/wp-content/uploads/2025/02/ART11.2.png1471960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-02-11 08:40:452025-02-11 08:40:45DAROLUTAMIDE IN COMBINATION WITH ANDROGEN-DEPRIVATION THERAPY IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER FROM THE PHASE III ARANOTE TRIAL.
https://www.aigom.it/wp-content/uploads/2025/02/Screenshot-2025-02-04-102819.png791564Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-02-04 09:29:352025-02-04 09:29:35AIGOM PROGETTO CANOA 2025-CARCINOMA MAMMARIO: QUALI NOVITA’ NEL 2025?
https://www.aigom.it/wp-content/uploads/2025/02/ART.04.02.png1254960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-02-03 09:18:082025-02-03 09:18:08CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN NON-SMALL CELL LUNG CANCER WITH PD-L1≥ 1 %: A SUBGROUP ANALYSIS FROM THE EMPOWER-LUNG 3 PART 2 TRIAL.
